'More Than 400 Grail Patients Incorrectly Told They May Have Cancer' - Financial Times
Portfolio Pulse from Benzinga Newsdesk
Over 400 patients of Grail, a cancer detection startup, were incorrectly informed they may have cancer due to a software error. Grail is a subsidiary of Illumina, a biotechnology company.
June 02, 2023 | 7:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Illumina's subsidiary Grail faced a software error that led to over 400 patients being incorrectly informed they may have cancer.
The software error at Grail, a subsidiary of Illumina, has led to a significant number of patients receiving incorrect information about their cancer risk. This could negatively impact Illumina's reputation and potentially affect its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100